| dbo:abstract |
أولاراتوماب هو جسم مضاد وحيد النسيلة، طورته شركة إمكلون ثم ليلي لعلاج الأورام الصلبة. في فبراير 2015، حصل على صفة دواء يتيم من وكالة الأدوية الأوروبية لعلاج . وفي أكتوبر 2016، أصدرت إدارة الغذاء والدواء الأمريكية تنويها بترخيص استعماله مع دوكسوروبيسين لعلاج أنواع معينة من ساركوما النسيج الرخو. (ar) L’olaratumab (nom commercial : Lartruvo) est un anticorps monoclonal en cours d’évaluation pour le traitement de tumeurs solides. Il est dirigé contre le platelet-derived growth factor receptor alpha. (fr) Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses"). (en) |
| dbo:alternativeName |
Lartruvo (en) |
| dbo:casNumber |
1024603-93-7 |
| dbo:drugbank |
DB06043 |
| dbo:fdaUniiCode |
TT6HN20MVF |
| dbo:kegg |
D09939 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/olaratumab |
| dbo:wikiPageID |
26602636 (xsd:integer) |
| dbo:wikiPageLength |
10071 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1063473347 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cytochrome_P450 dbr:Cancer_surgery dbr:Median dbr:Nausea dbr:Orphan_drug dbr:PDGFRA dbr:Eli_Lilly_and_Company dbr:Monoclonal_antibody dbr:Lymphopenia dbr:Statistical_significance dbr:P-value dbr:Progression-free_survival dbc:Orphan_drugs dbr:Doxorubicin dbr:European_Commission dbr:European_Medicines_Agency dbr:European_Union dbr:FDA dbr:Breakthrough_therapy dbr:Fast_track_(FDA) dbc:Withdrawn_drugs dbr:Hypersensitivity dbr:Mucositis dbc:Breakthrough_therapy dbc:Eli_Lilly_and_Company_brands dbc:Monoclonal_antibodies_for_tumors dbr:Accelerated_approval_(FDA) dbr:Biological_half-life dbr:Soft-tissue_sarcoma dbr:Pharmacokinetic dbr:Radiation_therapy dbr:Randomised_controlled_trial dbr:Volume_of_distribution dbr:Neutropenia dbr:Neutrophil dbr:ImClone_Systems dbr:Platelet-derived_growth_factor_receptor dbr:Tyrosine_kinase dbr:Intravenous_infusion dbr:Priority_review_(FDA) dbr:Proteolytic_enzyme dbr:Transmembrane_pump dbr:Phase_I_clinical_trial dbr:Platelet-derived_growth_factor_receptor_alpha dbr:Solid_tumor |
| dbp:atcPrefix |
L01 (en) |
| dbp:atcSuffix |
FX10 (en) |
| dbp:c |
6554 (xsd:integer) |
| dbp:casNumber |
1024603 (xsd:integer) |
| dbp:chemspiderid |
None (en) |
| dbp:dailymedid |
Lartruvo (en) |
| dbp:drugbank |
DB06043 (en) |
| dbp:eliminationHalfLife |
950400.0 (dbd:second) |
| dbp:h |
10076 (xsd:integer) |
| dbp:kegg |
D09939 (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:mabType |
mab (en) |
| dbp:metabolism |
Proteolytic enzymes (en) |
| dbp:n |
1736 (xsd:integer) |
| dbp:o |
2048 (xsd:integer) |
| dbp:proteinBound |
None (en) |
| dbp:routesOfAdministration |
dbr:Intravenous_infusion |
| dbp:s |
40 (xsd:integer) |
| dbp:source |
u (en) |
| dbp:synonyms |
IMC-3G3, LY-3012207 (en) |
| dbp:target |
dbr:PDGFRA |
| dbp:tradename |
Lartruvo (en) |
| dbp:type |
mab (en) |
| dbp:unii |
TT6HN20MVF (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
458283639 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Drugs.com dbt:Growth_factor_receptor_modulators dbt:Monoclonals_for_tumors |
| dct:subject |
dbc:Orphan_drugs dbc:Withdrawn_drugs dbc:Breakthrough_therapy dbc:Eli_Lilly_and_Company_brands dbc:Monoclonal_antibodies_for_tumors |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment |
أولاراتوماب هو جسم مضاد وحيد النسيلة، طورته شركة إمكلون ثم ليلي لعلاج الأورام الصلبة. في فبراير 2015، حصل على صفة دواء يتيم من وكالة الأدوية الأوروبية لعلاج . وفي أكتوبر 2016، أصدرت إدارة الغذاء والدواء الأمريكية تنويها بترخيص استعماله مع دوكسوروبيسين لعلاج أنواع معينة من ساركوما النسيج الرخو. (ar) L’olaratumab (nom commercial : Lartruvo) est un anticorps monoclonal en cours d’évaluation pour le traitement de tumeurs solides. Il est dirigé contre le platelet-derived growth factor receptor alpha. (fr) Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses"). (en) |
| rdfs:label |
أولاراتوماب (ar) Olaratumab (fr) Olaratumab (en) |
| owl:sameAs |
freebase:Olaratumab yago-res:Olaratumab wikidata:Olaratumab dbpedia-ar:Olaratumab dbpedia-fa:Olaratumab dbpedia-fr:Olaratumab https://global.dbpedia.org/id/4ss8V |
| prov:wasDerivedFrom |
wikipedia-en:Olaratumab?oldid=1063473347&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Olaratumab |
| is dbo:wikiPageRedirects of |
dbr:Lartruvo |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:List_of_human_clusters_of_differentiation dbr:PDGFRA dbr:Monoclonal_antibody_therapy dbr:Nomenclature_of_monoclonal_antibodies dbr:ATC_code_L01 dbr:Lartruvo dbr:List_of_therapeutic_monoclonal_antibodies dbr:Undifferentiated_pleomorphic_sarcoma dbr:List_of_drugs:_O–Op |
| is foaf:primaryTopic of |
wikipedia-en:Olaratumab |